Pulmatrix Inc
pulmatrix.comWhat Do They Do?
Develops inhaled drug candidates for migraine and lung diseases using an engineered dry-powder delivery platform.
10-K for FY2025, filed Feb 26, 2026
Who Are Their Customers?
MannKind Corporation and Cipla Technologies license iSPERSE™ for certain fields of use. Cipla is developing PUR1900 outside the United States, while Pulmatrix and Cipla share U.S. rights.
8-K, filed Aug 13, 2026iSPERSE™, also licensed to MannKind Corporation and Cipla Technologies for certain fields of use, utilizes particles that are engineered…View ↗
PUR1900, has been approved to proceed to a Phase 3 in India conducted by our partner Cipla. This is the Company’s inhaled iSPERSE™…View ↗
Pulmatrix will receive 2% royalties on any potential future net sales by Cipla outside the United States should Cipla successfully market…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$1MView ↗
- ▼ −33% (Loss)
- vs −$1.5M in Q2 FY2025
-
Aug 13, 2026
Pulmatrix filed an S-4 for its proposed Eos merger
The merger is anticipated to close in the third quarter of 2026, subject to customary closing conditions.
Sources
8-K, filed Aug 13, 2026
Form S-4 filed related to the announced merger agreement with Eos SENOLYTIXView ↗
-
Mar 27, 2026
Pulmatrix agreed to acquire Eos SENOLYTIX
Eos would become its wholly owned subsidiary, and the combined company is expected to operate as Eos SENOLYTIX.
Sources
8-K, filed Mar 27, 2026
On March 26, 2026, Pulmatrix, Inc., a Delaware corporation (“Pulmatrix” or the “Company”), entered into an Agreement and Plan of Merger and…View ↗
-
Mar 2, 2026
Cullgen terminated its proposed merger with Pulmatrix
Pulmatrix said it would continue pursuing alternative merger opportunities.
Sources
8-K, filed Mar 2, 2026
On February 28, 2026, Pulmatrix, Inc. (the “Company” or “Pulmatrix”) received a termination notice (the “Notice”) from Cullgen Inc.…View ↗
Development to asset monetization
The older report describes active clinical development of inhaled candidates; the latest says development is paused while Pulmatrix seeks to monetize its iSPERSE technology and clinical assets.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Feb 26, 2026We expect to continue to incur significant expenses and operating losses for at least the next several years based on our drug development…View ↗
Conduct PUR1900 clinical trials focused on the development of an inhaled antifungal therapy to treat an allergic/hypersensitivity response…View ↗
Pursue further clinical studies for PUR3100, an orally inhaled dihydroergotamine (“DHE”) including a Phase 2 clinical study for the…View ↗
Loading...
